Study on Risk Assessment and Follow-Up for Hepatitis B Virus-Related Liver Cancer Using AI and Multimodal Data

What This Trial Is About

Liver cancer is a serious health problem worldwide, with China having the highest rates of cases and deaths. This research focuses on people at high risk of liver cancer due to chronic hepatitis B virus HBV infection. The goal is to use advanced data analysis and artificial intelligence AI to improve early detection and manage care for these high-risk individuals through a large, multi-center study. Participants will be monitored through two groups one receiving routine follow-up every 24 weeks, or more frequently every 8-12 weeks if considered extremely high risk, and the other followed up by an AI system on the same schedule. At each visit, tests such as alpha fetoprotein, PIVKA-II, liver imaging, and liver function assessments will be performed to track liver health and cancer risk. During the study, participants will undergo regular check-ups with blood tests and imaging to monitor liver condition. The research team will track how many participants develop liver cancer within five years and measure survival times. The study includes careful follow-up and management for up to five years to observe outcomes and improve monitoring strategies using AI technology.

Risk Assessment for HBV-Related Liver Cancer